Bausch Health Companies Inc (NYSE:BHC) CEO Joseph C. Papa purchased 30,000 shares of the company’s stock in a transaction dated Friday, September 13th. The stock was bought at an average price of $23.31 per share, with a total value of $699,300.00.

Shares of Bausch Health Companies stock opened at $23.19 on Thursday. The firm has a market capitalization of $8.22 billion, a price-to-earnings ratio of 5.49, a PEG ratio of 0.28 and a beta of 0.80. Bausch Health Companies Inc has a fifty-two week low of $17.20 and a fifty-two week high of $28.45. The company has a debt-to-equity ratio of 8.94, a quick ratio of 0.92 and a current ratio of 1.21. The stock has a 50 day moving average of $22.27 and a 200 day moving average of $23.48.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $1.03 earnings per share for the quarter, missing the consensus estimate of $1.06 by ($0.03). The business had revenue of $2.15 billion during the quarter, compared to analysts’ expectations of $2.15 billion. Bausch Health Companies had a positive return on equity of 52.12% and a negative net margin of 10.88%. The company’s revenue was up 1.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.93 earnings per share. Analysts forecast that Bausch Health Companies Inc will post 4.24 EPS for the current year.

Institutional investors have recently modified their holdings of the stock. First Allied Advisory Services Inc. boosted its position in shares of Bausch Health Companies by 2.8% during the first quarter. First Allied Advisory Services Inc. now owns 18,341 shares of the company’s stock worth $453,000 after buying an additional 498 shares during the period. Investors Research Corp boosted its position in shares of Bausch Health Companies by 85.7% during the second quarter. Investors Research Corp now owns 1,300 shares of the company’s stock worth $33,000 after buying an additional 600 shares during the period. Cullinan Associates Inc. boosted its position in shares of Bausch Health Companies by 1.5% during the second quarter. Cullinan Associates Inc. now owns 47,033 shares of the company’s stock worth $1,186,000 after buying an additional 700 shares during the period. Pictet Asset Management Ltd. boosted its position in shares of Bausch Health Companies by 0.6% during the second quarter. Pictet Asset Management Ltd. now owns 115,664 shares of the company’s stock worth $2,924,000 after buying an additional 700 shares during the period. Finally, B & T Capital Management DBA Alpha Capital Management boosted its position in shares of Bausch Health Companies by 1.5% during the second quarter. B & T Capital Management DBA Alpha Capital Management now owns 56,292 shares of the company’s stock worth $1,420,000 after buying an additional 834 shares during the period. Institutional investors own 56.04% of the company’s stock.

BHC has been the subject of a number of analyst reports. Guggenheim initiated coverage on Bausch Health Companies in a research report on Thursday, September 12th. They issued a “buy” rating and a $30.00 price target for the company. Mizuho set a $45.00 price target on Bausch Health Companies and gave the company a “buy” rating in a research report on Thursday, June 20th. TD Securities upgraded Bausch Health Companies from a “hold” rating to a “buy” rating and set a $28.00 price target for the company in a research report on Thursday, August 15th. HC Wainwright upped their price target on Bausch Health Companies from $50.00 to $54.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Finally, Barclays set a $28.00 price target on Bausch Health Companies and gave the company a “buy” rating in a research report on Monday, July 8th. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and twelve have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $29.68.

About Bausch Health Companies

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Featured Article: Net Income

Insider Buying and Selling by Quarter for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.